Zealand's hypoglycemia candidate meets in second Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a second Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation of dasiglucagon, a stable glucagon analog, in the ready-to-use HypoPal rescue pen.

On the primary endpoint, a single injection of subcutaneous dasiglucagon significantly increased median time to blood glucose recovery, defined as the first increase in plasma glucose of at least 20 mg/dL from baseline without administration of rescue IV glucose, vs. placebo (10 vs. 40 minutes, p<0.001). Median time to blood glucose recovery was 12 minutes for the active comparator subcutaneous GlucaGen (native glucagon powder) from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO)...